

Understanding

CAR T-cell therapy

Saturday 21st November 2020, Lymphoma Australia invites you to register for our FREE live webinar.

About this event

Join us to learn more about what is CAR T-cell and have your questions answered about:

- [How CAR T-cell therapy works](#)
- [Side effects of CAR T-cell therapy](#)
- [What subtypes are currently being treated](#)
- [CAR T-cell therapy funding in Australia](#)
- [Clinical trials available around the world and in Australia](#)

Dr Michael Dickinson

Peter MacCallum Cancer Centre & Royal Melbourne Hospital, Melbourne

Dr Michael Dickinson is a haematologist, and the disease group lead of aggressive lymphoma at Peter MacCallum Cancer centre & RMH. Dr Dickinson has a special interest in lymphoma and is leading the development of new targeted, non-chemotherapy drugs as the principal investigator of many trials of new treatments. He is the local investigator on a range of CAR T-cell therapy trials. Dr Dickinson has been instrumental in helping in the recent approval of publicly funded CAR T-cell therapy to Australian patients.



Details

- Date:** Saturday 21st November
Time: 11 am–12 pm (ADST VIC/NSW/TAS)
Venue: This is a virtual (Zoom webinar) event
RSVP: Register your interest to join this session on the [website](#)

For more information or questions, please contact **1800 953 081** or email: nurse@lymphoma.org.au